Arbutus to Participate in September Investor Conferences
WARMINSTER, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York:
H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)
- Company Presentation: Tuesday, September 13th at 12:30 pm ET
- Presenter: William Collier, President & Chief Executive Officer
Baird’s 2022 Global Healthcare Conference (September 13-14, 2022)
- Fireside Chat: Wednesday, September 14th at 10:15 am ET
- Presenters: William Collier, President & Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Michael McElhaugh, Chief Business Officer; and David Hastings, Chief Financial Officer
Live webcasts of the presentation and fireside chat can be accessed through the Investors section of Arbutus' website at . An archived replay of the webcast will be available on the Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, we are developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that we intend to combine to provide a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio. For more information, visit .
Contact Information
Investors and Media
William H. Collier
President and CEO
Phone: 267-469-0914
Email:
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email:
